Clinical Trials Logo

Embolism, Pulmonary clinical trials

View clinical trials related to Embolism, Pulmonary.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05770232 Completed - Rib Fractures Clinical Trials

Retrospectively Analyze the Risk Factors of VTE in 5774 Patients With Thoracic Trauma From 33 Hospitals in China, and Established a Risk Prediction Model

MCTTVTE
Start date: September 1, 2019
Phase:
Study type: Observational

Retrospectively analyze the risk factors of VTE in 5774 patients with thoracic trauma from 33 hospitals in China, and established a risk prediction model

NCT ID: NCT01258140 Completed - Embolism, Pulmonary Clinical Trials

Detection of Pulmonary Embolism With Low-dose CT Pulmonary Angiography

REDOPED
Start date: September 2008
Phase: N/A
Study type: Interventional

Computed tomography pulmonary angiography (CTPA) is the imaging method of choice to rule out acute pulmonary embolism based on its high sensitivity and specificity. Unfortunately, CTPA uses iodinated contrast media and can provoke contrast induced nephropathy. On the other hand, Computed tomography uses ionising radiation and is responsible for the half of the radiation exposure coming from medical sources. Recent studies have proven that low-dose CTPA protocols using Computed tomography tube energy of 80 kVp and reduced volume of iodinated contrast media provide an increased vessel signal and good image quality at a significantly reduced patient exposure. However, there are no data on the sensitivity of low-kVp protocols. The aim of this prospective randomized trial is to detect any difference between a normal-dose and a low-dose CTPA protocol in the diagnostic accuracy in the detection of acute pulmonary embolism (PE).

NCT ID: NCT00981409 Completed - Embolism, Pulmonary Clinical Trials

The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

Start date: July 2007
Phase: Phase 3
Study type: Interventional

The primary objective is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism [VTE] (i.e., Pulmonary thromboembolism [PE] and Deep Vein Thrombosis [DVT])) and safety of GSK576428 as the initial treatment in subjects with acute PE in an open-label design.